Both in Biotechnology
Prime Medicine vs Allogene Therapeutics
Over the past year PRME returned −41.9% and ALLO returned +27.6%; their daily moves had a correlation of 0.41.
PRME −41.9% ALLO +27.6%Growth of $1, one year, split-adjusted
| Metric | PRME | ALLO |
|---|---|---|
| Price | $3.09 | $1.62 |
| Market cap | $560.5M | $559.7M |
| Today | +7.48% | −0.61% |
| 1 month | −14.4% | −19.8% |
| 6 months | −1.9% | −27.0% |
| Year to date | −11.0% | +18.2% |
| 1 year | −39.6% | +29.6% |
| Revenue growth (YoY) | +3.5% | — |
| Gross margin | 100.0% | 100.0% |
| Net margin | −3649.0% | −919.8% |
| P/E (TTM) | — | — |
| Price / sales | 137.6× | 120.6× |
| Net cash | $95.1M | $332.6M |
| Dividend yield | — | — |
| Volatility (60d) | 85.9% | 57.7% |
| Short % of float | 33.6% | 21.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).